Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyW. Fraser Symmans, Lajos Pusztai|Journal of Clinical Oncology|2007Cited by 1.6k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO GuidelineLarissa A. Korde, Dawn L. Hershman, Mark R. Somerfield et al.|Journal of Clinical Oncology|2021Cited by 991
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Gillian L. Hirst et al.|Cancer Cell|2021Cited by 330